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SYSTEMATIC REVIEW AND META-ANALYSIS
Prognostic Value of Abdominal Aortic 
Calcification: A Systematic Review and 
Meta-Analysis of Observational Studies
Kevin Leow , MBBS*; Pawel Szulc, MD, PhD*; John T. Schousboe, MD, PhD; Douglas P. Kiel , MD, MPH; 
Armando Teixeira-Pinto, PhD; Hassan Shaikh; Michael Sawang; Marc Sim , PhD; Nicola Bondonno , PhD; 
Jonathan M. Hodgson, PhD; Ankit Sharma, MD; Peter L. Thompson, MD; Richard L. Prince, MD;  
Jonathan C. Craig, MD, PhD; Wai H. Lim, MD, PhD; Germaine Wong, MD, PhD; Joshua R. Lewis , PhD
BACKGROUND: The prognostic importance of abdominal aortic calcification (AAC) viewed on noninvasive imaging modalities 
remains uncertain.
METHODS AND RESULTS: We searched electronic databases (MEDLINE and Embase) until March 2018. Multiple reviewers iden-
tified prospective studies reporting AAC and incident cardiovascular events or all-cause mortality. Two independent reviewers 
assessed eligibility and risk of bias and extracted data. Summary risk ratios (RRs) were estimated using random-effects mod-
els comparing the higher AAC groups combined (any or more advanced AAC) to the lowest reported AAC group. We identi-
fied 52 studies (46 cohorts, 36 092 participants); only studies of patients with chronic kidney disease (57%) and the general 
older-elderly (median, 68 years; range, 60–80 years) populations (26%) had sufficient data to meta-analyze. People with any or 
more advanced AAC had higher risk of cardiovascular events (RR, 1.83; 95% CI, 1.40–2.39), fatal cardiovascular events (RR, 
1.85; 95% CI, 1.44–2.39), and all-cause mortality (RR, 1.98; 95% CI, 1.55–2.53). Patients with chronic kidney disease with any 
or more advanced AAC had a higher risk of cardiovascular events (RR, 3.47; 95% CI, 2.21–5.45), fatal cardiovascular events 
(RR, 3.68; 95% CI, 2.32–5.84), and all-cause mortality (RR, 2.40; 95% CI, 1.95–2.97).
CONCLUSIONS: Higher-risk populations, such as the elderly and those with chronic kidney disease with AAC have substantially 
greater risk of future cardiovascular events and poorer prognosis. Providing information on AAC may help clinicians under-
stand and manage patients’ cardiovascular risk better.
Key Words: abdominal aortic calcification ■ all-cause mortality ■ cardiovascular events and deaths ■ chronic kidney disease  
■ general population
The presence of coronary artery calcification, an es-tablished marker of subclinical atherosclerosis, has been shown to predict future risk of cardiovascular 
events and mortality.1 Calcifications in other extracoro-
nary vascular beds such as the carotid, iliac, and ab-
dominal aorta are also common, but fewer studies have 
investigated the prognostic importance of these calci-
fied vascular lesions. Vascular calcification at these sites 
is often observed in high-risk patients such as those 
with advanced age, diabetes mellitus, advanced athero-
sclerosis, or chronic kidney disease (CKD). A number of 
noninvasive, safe, and widely available modalities can 
be used to assess vascular calcification at these sites, 
particularly of the abdominal aorta.2
The abdominal aorta is one of the first vascular 
beds where atherosclerotic calcification is observed, 
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often preceding the development of coronary ar-
tery calcification.3,4 Population-based studies have 
found abdominal aortic calcification (AAC) occurs 
in ≈1 in 3 people aged 45 to 54  years and up to 9 
in 10 people aged over 75 years.5 For older patients 
with type 2 diabetes mellitus or CKD requiring dialy-
sis, the prevalence ranges between 84% and 97%.6–8 
AAC can be assessed by computed tomography (CT) 
or lateral spine images from standard radiographs or 
dual-energy x-ray absorptiometry (DXA) machines. 
Associations between AAC and cardiovascular events 
were reported in a wide range of clinical settings such 
as middle-aged to older men and women from the 
general population,9–11 individuals with type 2 diabetes 
mellitus,12 and patients with CKD.6 Some, but not all, 
reports have suggested that the magnitude of risk for 
cardiovascular events, fatal cardiovascular events, and 
all-cause mortality depends on the amount of AAC vis-
ible on imaging tests, with the greatest risk found in 
patients with the most advanced calcification.9,13,14
However, these studies are relatively small and 
report on a limited number of clinically meaningful 
outcomes. To date, most systematic reviews and 
meta-analyses have focused on a single clinical 
population,15,16 and few attempts have been made 
to summarize and integrate data from all published 
studies to identify clinically important differences 
among studies, identify subsets of patients where 
AAC is more or less clinically important, and identify 
areas where more research is needed. As such, we 
undertook this systematic review and meta-analysis.
We hypothesized that people with AAC would have a 
greater risk of cardiovascular events, fatal cardiovascular 
events, and poorer prognosis. Additionally, we sought to 
determine the strength of this association and whether 
this varied across different clinical settings using differ-
ent imaging modalities and in populations with varying 
comorbid factors such as older age, sex, diabetes melli-
tus, smoking, hypertension, and dyslipidemia.
METHODS
This systematic review and meta-analysis was writ-
ten and reported in adherence to the Meta-analysis of 
Observational Studies in Epidemiology17 reporting crite-
ria. All data relevant to this study are available from the 
corresponding author upon reasonable request.
Inclusion and Exclusion Criteria
We included any cohort or case-control study that re-
ported the association between AAC and any cardio-
vascular outcomes such as coronary heart disease, 
cerebrovascular disease, heart failure, peripheral 
arterial disease and the like, or all-cause mortality. 
We excluded cross-sectional studies and reviews of 
existing literature.
Search Strategy and Process for 
Selecting Studies
A comprehensive literature search within MEDLINE and 
Embase databases was conducted to source all possibly 
relevant studies for review, without language restriction, 
until March 2018. Conference proceedings and abstracts 
were evaluated, and a hand search of reference lists was 
undertaken. The search terms were combined with 
the Boolean “AND” to find all potentially relevant stud-
ies. When >1 publication for a study was retrieved, arti-
cles with the most up-to-date and complete information 
were included, although additional unique data from all 
sources were considered and included when relevant. 
Examples of the search strategy are shown in Table S1. 
At least 2 investigators independently retrieved and as-
sessed citations for eligibility, assessed the risk of bias, 
and extracted the data (K.L., P.S., H.S., or M.S.), and an-
other investigator was sought when agreement could not 
be reached (J.R.L.).
Risk of Bias and Level of Evidence 
Assessment
The risk of bias was assessed using the Newcastle-
Ottawa Scale for case-control and cohort studies 
CLINICAL PERSPECTIVE
What Is New?
• We demonstrate that the presence and severity of 
abdominal aortic calcification detected using any 
imaging modality is an underappreciated measure 
of structural vascular disease that identifies people 
with substantially higher risk of clinical cardiovas-
cular events and poorer long-term prognosis.
What Are the Clinical Implications?
• Fortuitous findings of abdominal aortic calcifi-
cation in patients with no known disease or in-
formation on cardiovascular risk factors, should 
be considered to be an indication for diagnostic 
testing such as lipid assays, ECG, or further di-
agnostic imaging (ie, coronary artery calcifica-
tion scores).
Nonstandard Abbreviations and Acronyms
AAC abdominal aortic calcification
ARD absolute risk difference
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and included the following domains: representative-
ness of the exposed population, appropriate selec-
tion and comparison of the study groups, adequate 
ascertainment of exposure, and whether the com-
parability of the cohorts was evaluated appropriately 
with detailed assessment of all outcomes within an 
appropriate follow-up time. At least 2 investigators 
independently assessed risk of bias (K.L., M.S., 
H.S., or J.R.L.). Summary estimates of the confi-
dence placed on the evidence were evaluated using 
the Grading of Recommendations Assessment 
Development and Evaluation of evidence about 
prognosis. Unlike Grading of Recommendations 
Assessment Development and Evaluation for clinical 
practice guidelines where observational evidence 
starts at low-quality evidence and can then be rated 
up or down, the Grading of Recommendations 
Assessment Development and Evaluation for evi-
dence about prognosis for observational studies 
starts with high-quality evidence. These criteria are 
based on (1) 5 domains diminishing confidence (−1 
for risk of bias, inconsistency, imprecision, indirect-
ness, and publication bias) and (2) 2 situations in-
creasing confidence (+1 or +2 for large–very large 
effect size and a +1 for a dose-response gradient 
[increasing pooled relative risks for cardiovascu-
lar events and all-cause mortality with increasing 
severity of AAC]).18 Details of how the Grading of 
Recommendations Assessment Development and 
Evaluation assessments were performed are pro-
vided in Tables S2 and S3.
AAC Reporting
AAC was reported either quantitatively (computed 
tomography) or semiquantitatively (x-ray and DXA). 
We used the group with the lowest reported AAC as 
the referent and combined all other reported groups 
(any or more advanced AAC) to calculate the ab-
solute risk difference (ARD) and relative risk for any 
cardiovascular outcomes or all-cause mortality. This 
approach was required because of different severity 
or distribution thresholds used to define categories of 
AAC (Tables S4 and S5). In secondary analyses, we 
analyzed studies that reported AAC by either (1) the 
absence versus the presence of AAC to determine 
the association between any AAC and outcomes or 
(2) studies that reported ≥3 categories of AAC for 
assessing whether a “dose-response” gradient was 
evident. Where data for >3 categories of AAC were 
available, we collapsed the middle groups and as-
signed them as “moderate AAC.” To further address 
thresholds of AAC we used the R package for the 
meta-analysis of diagnostic accuracy (“mada”) to cal-
culate the bivariate summary receiver operator char-
acteristic (sROC) curves with default parameters.19,20 
sROC converts paired sensitivity and specificity into a 
single measure of accuracy (diagnostic odds ratio).20
Data Synthesis and Statistical Analysis
Where cardiovascular event data were reported in 
individual studies, pooled risk differences and risk 
ratios (RRs) with 95% CIs were calculated, from 
which a summary estimate was determined using 
DerSimonian-Laird random-effects models using 
Comprehensive Meta-Analysis, Version 3.21 We 
chose the random-effects model over the fixed-ef-
fects as a more conservative approach in the pres-
ence of heterogeneity. However, we also performed 
the main analyses using fixed effects. Heterogeneity 
was investigated using the I2 statistic.22,23 We consid-
ered the I2 thresholds of <25%, 25% to 49%, 50% to 
75%, and >75% to represent low, moderate, high, and 
very high heterogeneity, respectively. The likelihood 
of publication bias was evaluated by visual inspec-
tion of funnel plots and using the Egger regression 
test.24 To understand how adjusting for traditional 
cardiovascular risk factors may affect the pooled re-
sults, we extracted adjusted estimates of risk from 
individual studies (hazard ratio or odds ratio) of the 
general population, see Table  S6 for adjustments 
used in each study.
Subgroup Analysis and Meta-Regression
We used subgroup analysis to investigate clinical het-
erogeneity (general population, CKD, or other and age 
of cohort <60, 60–69, and ≥70 years) and methodo-
logical heterogeneity (risk of bias of studies, imaging 
modality [radiograph, DXA, or CT] and duration of 
follow-up <5, 5–9, ≥10  years). Meta-regression was 
also conducted using a random effects model in the 
subgroup categories above and with the variables pre-
sented in Table 1 such as mean cohort systolic blood 




Of the 458 potentially eligible publications, 52 stud-
ies (50 cohort studies and 2 case-control studies; 
total number of individuals, 36 092) met the eligibil-
ity criteria.6,8–14,25–68 Details of the individual studies 
are provided in Table  2. The interreviewer level of 
agreement regarding eligibility of included studies 
was very good (κ=0.97). Four cohorts had multiple 
eligible publications (Framingham Heart Study [n=4], 
Rotterdam Study [n=2], MINOS study [n=2] and 
PERF (Prospective Epidemiological Risk Factors) 
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and Figure 1). A total of 32 publications (29 cohorts) 
provided extractable data for quantitative synthesis.
Newcastle-Ottawa Scale Risk of Bias
For the 52 cohort and case-control studies, the overall 
risk of bias was considered low to moderate for com-
parability. For the selection and outcomes domains, 
the risk of bias was considered moderate to high. 
Detailed risk of bias assessment and results are pre-
sented in Data S1 and Figure S1.
Characteristics of Included Studies
Most studies were published in 2011 or later and repre-
sented cohorts of <500 people. Over half (57%) of the 
studies were in patients with CKD (estimated glomer-
ular filtration rate <60 mL/min per 1.73 m2 to dialysis) 
and kidney transplant recipients, 26% were from the 
general population, 4% patients with diabetes mellitus, 
and 13% from other clinical settings (Table 1). AAC was 
evaluated by radiograph in 46% of studies, 37% by CT, 
11% DXA, and 6% by ultrasound or 2 separate imaging 
modalities. Follow-up time in the cohorts ranged from 1 
to 22 years, with a median follow-up time of 6.5 years.
Reporting of AAC
AAC was reported in a number of different ways for x-
rays and DXA (presence versus absence, AAC 8 scores, 
AAC 24 scores, or measured length of calcification). For 
CT, AAC was reported as presence versus absence, 
percentiles of the cohort, calcium scores, or AAC index, 
as outlined in Table 2. Cut points for individual studies 
that contributed data for incident events—cardiovascu-
lar events (n=16), fatal cardiovascular events (n=11), all-
cause mortality (n=17), cerebrovascular events (n=5), and 
coronary heart disease (n=6)—are shown in Table S4 (x-
ray and DXA) and Table S5 (CT). There were insufficient 
studies reporting AAC for all other cardiovascular out-
comes. Absolute risk differences and relative risk differ-
ences for each individual study are presented in Table 3.
Clinical Heterogeneity
A priori subgroup analyses (CKD versus general popu-
lation) identified clinical heterogeneity attributable to 
the participants recruited (data not shown). This was 







Chronic kidney disease 26 (57)
General population 12 (26)
Other 8 (17)
Region














Not specified 1 (2)
Test characteristics
Modality of assessing abdominal aortic calcification
X-ray 22 (48)
Quantitative computed tomography 17 (37)







Not specified 2 (4)
Sex
All male 1 (2)
All female 4 (9)
Mixed 39 (85)
Not specified 2 (4)
Prevalence of diabetes mellitus
<10% 13 (28)
≥10% 30 (65)
Not specified 3 (7)
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confirmed in meta-regression analyses where the type 
of population recruited potentially explained 32% to 
50% of the observed between-study heterogeneity 
for cardiovascular events (r2=50%), fatal cardiovascu-
lar events (r2=34%), and all-cause mortality (r2=32%). 
As there is no recommended approach when clinical 
heterogeneity is identified,69 we decided post hoc to 
undertake all further analyses in studies of patients 
with CKD and the general population separately. There 
were insufficient numbers of studies (n=2) to meta-an-
alyze in the “other” populations for any outcome.
AAC, Cardiovascular Events, Fatal 
Cardiovascular Events, and All-Cause 
Mortality in Studies From the General 
Population
Extractable data were available for 6 studies (n=8498) 
for cardiovascular events,9–11,13,14,25 5 studies 
(n=8004) for fatal cardiovascular events,9,10,13,29,31 and 
6 studies (n=8662) for all-cause mortality.9,10,25,29,30,58 
Compared with those with no or low AAC, people 
with any or more advanced AAC had higher pooled 
Figure 1. Study flow.
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absolute risk differences for cardiovascular events 
(+9.9%; 95% CI, +4.1%–15.8%), fatal cardiovascular 
events (+8.6%; 95% CI, +2.3%–14.8%), and all-cause 
mortality (+17.4%; 95% CI, +8.1%–26.6%). The sum-
mary table of evidence is provided in Table 4. Briefly, 
the pooled RRs were 1.83 (95% CI, 1.40–2.39) for 
cardiovascular events, 1.85 (95% CI, 1.44–2.39) 
for fatal cardiovascular events, and 1.98 (95% CI, 
1.56–2.53) for all-cause mortality (moderate-quality 
evidence, all P<0.001). However, high (fatal cardio-
vascular events, I2=69%; cerebrovascular events, 
I2=60%; and coronary heart disease [CHD] events, 
I2=72%) to very high (cardiovascular events, I2=87%; 
and all-cause mortality, I2=90%) between-study het-
erogeneity was observed (Figure  2). Evidence of 
small-study publication bias was identified for all-
cause mortality (P=0.044). The sROC curves gener-
ated suggest that AAC alone may provide moderate 
to good (area under the curve, 0.69–0.75) discrimi-
native ability for cardiovascular events, fatal car-
diovascular events, and deaths in this population 
(Figure 3A, 3C and 3E).
Studies Reporting by Presence of AAC 
and Increasing AAC Severity From the 
General Population
There were 4 studies that reported AAC by the absence 
and presence of AAC for cardiovascular events,10,11,13,14 
4 studies for fatal cardiovascular events,10,13,29,31 and 5 
studies for all-cause mortality.10,25,29,30,58 Increased ab-
solute and relative risks were seen in people with any 
AAC (Table 5). Studies reporting ≥3 categories of AAC 
severity (cardiovascular events=5 studies,9,10,13,14,26 
fatal cardiovascular events=3 studies,2,11,14 and all-
cause mortality=3 studies9,10,13) had increased abso-
lute and relative risks with increasing severity of AAC 
(Table 5).
AAC, CHD, and Cerebrovascular Disease 
in Studies From the General Population
Extractable data were available for 5 studies (n=7766) 
for CHD9–11,13,26 and 4 studies (n=8943) for cerebro-
vascular disease.10,11,26,28 People with any or more 
advanced AAC had higher pooled absolute risk dif-
ferences for CHD (+7.4%; 95% CI, +2.0 to +12.8%) 
and cerebrovascular disease (+3.4%; 95% CI, +1.8 to 
+5.0%), compared with those with no or low AAC. The 
pooled RRs were 2.22 (95% CI, 1.57–3.15) for CHD 
events and 2.10 (95% CI, 1.41–3.12) for cerebrovascu-
lar events, Figure S2 (high-quality evidence [Tables 2 
and 5], both P<0.001), with moderate to high between-
study heterogeneity (60%–72%). Increasing absolute 
and relative risk with increasing severity of AAC were 
seen for CHD events (4 studies) and cerebrovascular 
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Pooled Analysis of Adjusted Estimates of 
Risk
To understand how adjusting for traditional cardio-
vascular risk factors may affect the pooled results we 
undertook meta-analyses using the reported adjusted 
estimates of risk from the individual studies (hazard 
ratio or odds ratio) interpreted as RR, using weighted 
random effects with similar results to the unadjusted 
analyses (Figure 4, Table 6).
Sources of Methodological and Statistical 
Heterogeneity
There was not statistically significant between-
study heterogeneity attributable to imaging modal-
ity (x-ray, DXA, CT), threshold AAC (present/absent, 
other), mean cohort age (<60, 60–69, ≥70  years), 
and duration of follow-up (<5, 5–9, ≥10 years; data 
not shown) (Figures S3, S4, and S5). Heterogeneity 
for cardiovascular and fatal cardiovascular events 
was potentially explained by mean cohort systolic 
blood pressure (42%–45%) and total cholesterol (4% 
and 13%) with greater RR differences seen in co-
horts with lower mean systolic blood pressure and 
total cholesterol. For fatal cardiovascular events, 
imaging modality potentially explained 60% of the 
heterogeneity with no between-group difference 
for studies using x-rays (2 studies) or DXA (2 stud-
ies), while 1 study using CT had the greatest RR. 
All-cause mortality studies with lower systolic blood 
pressure (39%) and shorter follow-up time (11%) had 
higher RR, while 1 study in Oceania had a lower RR 
than studies in Europe and the United States (36%). 
Additionally, studies with a higher prevalence of 
participants with diabetes mellitus at baseline had 
greater RR differences, potentially explaining 42% of 
the between-study heterogeneity.
AAC, Cardiovascular Events, Fatal 
Cardiovascular Events, and All-Cause 
Mortality in Patients With Chronic Kidney 
Disease
Extractable data were available for 8 studies (n=1426) 
for cardiovascular events,6,33,34,38,41,46,50,64 4 studies 
(n=1163) for fatal cardiovascular events,6,44,48,49 and 9 
studies (n=2050) for all-cause mortality.6,8,36,39,44,46–49 
Compared with those with no or low AAC, people with 
any or more advanced AAC had higher pooled absolute 
risk differences for cardiovascular events (+15.1%; 95% 
CI, +9.1%–21.1%), fatal cardiovascular events (+13.4%; 
95% CI, +3.8%–23.0%), and all-cause mortality (+17.1%; 
95% CI, +12.2%–22.0%). The pooled RRs were 3.47 
(95% CI, 2.21–5.45) for cardiovascular events, 3.69 
(95% CI, 2.32–5.85) for fatal cardiovascular events, 
and 2.41 (95% CI, 1.95–2.97) for all-cause mortality 
(moderate [cardiovascular events]-high [fatal cardiovas-
cular events and all-cause mortality] quality evidence 
[Table  2], all P<0.001), with no (fatal cardiovascular 
events and all-cause mortality) to low (cardiovascular 
events, 29%; P=0.196, attributable to a single study41) 
between-study heterogeneity (Figure  2). Evidence of 
small-study publication bias was identified for cardio-
vascular events (P=0.002). The sROC curves generated 
suggest that AAC alone may provide moderate to good 
(area under the curve, 0.64–0.83) discriminative ability 
for cardiovascular events, fatal cardiovascular events, 
and deaths in this population (Figure 3B, 3D, and 3F).




No. Studies (No. 
People)
Quality of the Evidence 
(GRADE)No or Low AAC





2/100 4/100 1.83 (1.40–2.39) 6 (8498) Moderate†
Fatal cardiovascular 
events
0/100 1/100 1.85 (1.44–2.39) 5 (8004) Moderate†
All-cause mortality 3/100 6/100 1.98 (1.55–2.53) 6 (8662) Moderate†
Patients with chronic kidney disease ‡
Cardiovascular 
events
4/100 14/100 3.47 (2.21–5.45) 8 (1426) Moderate†
Fatal cardiovascular 
events
1/100 4/100 3.68 (2.32–5.84) 4 (1163) High†
All-cause mortality 5/100 12/100 2.40 (1.95–2.97) 9 (2050) High†
*Baseline risk calculated from Criqui et al9 (n=1974), for cardiovascular events, fatal cardiovascular events, and all-cause mortality. AAC assessed by CT in 
men and women with a mean age of 65 years with a mean follow up of 5.5 years.
†Quality of evidence scoring based on GRADE for prognostic studies1 for all outcomes presented in Tables S6 and S7.
‡Baseline risk calculated from the Tatami et al6 (n=347), for cardiovascular events, fatal cardiovascular deaths, and all-cause mortality. AAC assessed by CT 
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Comparison of Fixed Versus Random 
Effects
The main analyses were performed using both fixed 
and random effects for comparative purposes and are 
presented in Table S7.
DISCUSSION
In this systematic review and meta-analysis, we ob-
served moderate- to high-quality evidence that people 
with any or more advanced AAC had substantially higher 
absolute and relative risk for cardiovascular events, fatal 
cardiovascular events, and all-cause mortality than 
people with no or less advanced AAC. The strongest 
associations were seen in patients with CKD and peo-
ple from the general population with the most advanced 
AAC. Importantly, AAC alone had moderate to good 
discrimination (sROC, 0.6–0.8) for all outcomes, indicat-
ing that this may be a clinically useful predictor of future 
cardiovascular events, fatal cardiovascular events, and 
prognosis in patients with CKD and the general popula-
tion. Thus, fortuitous findings of AAC in patients with 
no known data on cardiovascular risk factors should 
Figure 2. Association between abdominal aortic calcification (AAC) and cardiovascular disease events (CVD, A and B), fatal 
cardiovascular events (CV, C and D) and all-cause mortality (E and F) in cohorts from the general population (left panels) or 
patients with chronic kidney disease (CKD) (right panels).
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be considered to be an indication for further diagnostic 
testing, such as ECG, lipid assays, and so on.
Both a priori subgroup analysis and meta-regres-
sion identified that the risk in people with AAC differed 
substantially between studies recruiting patients with 
CKD versus those recruiting from the general popula-
tion. The strongest and most consistent associations 
were observed in patients with CKD. These findings 
may be attributable to a greater burden and progres-
sion of AAC in this patient group, differences in driv-
ers of calcification, or higher selected thresholds of 
AAC, which was particularly evident for cardiovascu-
lar events. Irrespective of the reasons, these findings 
add further support to the current Kidney Disease 
Improving Global Outcomes clinical practice guide-
lines suggesting that when AAC is seen in patients with 
Figure 3. Summary ROC (sROC) showing the point estimate (area under the curve [AUC]) for the diagnostic accuracy of AAC 
to identify people at risk of cardiovascular events (A and B), fatal cardiovascular events (C and D) and all-cause mortality (E 
and F) in cohorts from the general population (left panels) or patients with chronic kidney disease (CKD) (right panels).
Graphs are based on the paired sensitivity and false-positive rates plotted together with a confidence region (circled area). Each 
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CKD stages G3a–G5D (estimated glomerular filtration 
rate <60 mL/min per 1.73 m2 to dialysis), these patients 
should be considered at the highest cardiovascular 
disease risk.70
In cohorts recruited from the general population, 
people with any or more advanced AAC had twice the 
relative risk and 9% to 17% absolute risk difference for 
cardiovascular events, fatal cardiovascular events, and 
all-cause mortality compared with those in the low-
est reported AAC category. These very large absolute 
risk differences are likely attributable to the nature of 
the included cohorts, for example, elderly who are at 
high risk of these events. When meta-analyzing the 
adjusted measures of risk, the pooled RR remained 
similar, supporting the concept that AAC may provide 
additional prognostic information to conventional risk 
factors.9,27,57
While our sROC analyses demonstrated that AAC 
alone had moderate to good discrimination for all out-
comes, it did not address whether the addition of AAC 
to established risk factors improves prognostication. A 
number of the larger studies from the general popula-
tion have previously reported that the addition of AAC 
to conventional risk factors improves measures of dis-
crimination for cardiovascular events, cardiovascular 
mortality, CHD events, and ischemic strokes.9,57 In the 
Framingham offspring cohort, the inclusion of AAC led 
to a 12% improvement in net reclassification for both 
Table 5. Studies From the General Population With Different Thresholds
AAC Group
Number of Cohorts (No. Events/
No. Group)
Absolute Risk Difference 
(95% CI)




No detectable AAC 4 (485/2538) 1 (referent) 1 (referent)
Any AAC 4 (1361/3262) +11.4 (+1.7 to +21.0) 1.76 (1.32 to 2.34) 81%
Fatal cardiovascular events
No detectable AAC 4 (293/2105) 1 (referent) 1 (referent)
Any AAC 4 (971/3933) +10.4 (+4.4 to +16.3) 1.77 (1.47 to 2.13) 48%
All-cause mortality
No detectable AAC 5 (899/2225) 1 (referent) 1 (referent)
Any AAC 5 (2606/4471) +18.8 (+12.3 to +25.4) 1.72 (1.40 to 2.11) 84%
Increasing severity of AAC categories
Cardiovascular events
Lowest reported AAC group 5 (638/2952) 1 (referent) 1 (referent)
Middle/combined AAC 
group(s)
5 (735/2029) +6.5 (−0.2 to +13.3) 1.40 (1.06 to 1.84) 84%
Highest reported AAC group 5 (814/1773) +15.3 (+4.9 to +25.6) 2.06 (1.48 to 2.88) 90%
Fatal cardiovascular events
Lowest reported AAC group 3 (219/2400) 1 (referent) 1 (referent)
Middle/combined AAC 
group(s)
3 (314/1661) +6.7 (−1.3 to +14.8) 1.77 (1.24 to 2.52) 66%
Highest reported AAC group 3 (357/1472) +12.0 (−0.5 to +24.5) 2.61 (1.57 to 4.32) 81%
All-cause mortality
Lowest reported AAC group 3 (193/1674) 1 (referent) 1 (referent)
Middle/combined AAC 
group(s)
3 (244/1247) +5.5 (+0.5 to +10.5) 1.44 (1.13 to 1.84) 32%
Highest reported AAC group 3 (224/878) +17.5 (+5.1 to +29.8) 2.86 (1.30 to 6.28) 93%
Coronary heart disease
Lowest reported AAC 4 (299/2725) 1 (referent) 1 (referent)
Middle AAC group(s) 4 (382/1576) 5.6 (−0.4 to 11.6) 1.58 (1.16 to 2.16) 60%
Highest reported AAC 4 (458/1531) 10.7 (−1.3 to 22.8) 2.70 (1.47 to 4.97) 88%
Cerebrovascular disease
Lowest reported AAC 3 (105/2677) 1 (referent) 1 (referent)
Middle AAC group(s) 3 (163/2524) 2.5 (1.4 to 3.5) 1.72 (1.04 to 2.85) 65%
Highest reported AAC 3 (183/1971) 6.0 (3.8 to 8.2) 2.91 (1.51 to 5.62) 79%
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CHD and major cardiovascular events.27 Taken together 
with the sROC analyses showing moderate to good dis-
crimination, these findings suggest that the addition of 
AAC measures to Framingham risk factors are likely to 
improve discrimination for cardiovascular events.
In the general population, there was high be-
tween-study heterogeneity for cardiovascular events, 
fatal cardiovascular events, and all-cause mortality, 
suggesting that the summary estimates should be 
interpreted cautiously. This heterogeneity was poten-
tially attributable to cohort differences in systolic blood 
pressure and total cholesterol, with AAC being more 
prognostic in people with lower systolic blood pressure 
and total cholesterol, confirming findings in individual 
studies.14,71 This suggests that AAC may identify an 
as yet underappreciated high-risk group not captured 
by conventional risk factors. When meta-analyzing the 
adjusted measures of risk, heterogeneity was reduced 
for all outcomes.
Surprisingly, AAC imaging using x-ray, DXA, or CT 
and thresholds of AAC were not a major source of be-
tween-study heterogeneity for cardiovascular events 
or all-cause mortality. However, CT imaging was for 
cardiovascular death in the general population be-
cause of a single study of lower-risk individuals.9 This 
suggests that low-cost, widely available imaging mo-
dalities can be used to identify people at a clinically 
significantly increased risk of cardiovascular disease 
events and mortality. This is an important finding given 
the likely decline of standard radiographs, attributable 
to improvements in the image quality of DXA images 
at a fraction of the radiation dose of a standard radio-
graph and increasing access to CT as the radiation 
dose becomes lower.
Figure 4. Cardiovascular risk factor adjusted association between abdominal aortic calcification (AAC) and cardiovascular 
disease events (CVD) (A), fatal cardiovascular events (B), all-cause mortality (C), coronary heart disease events (D), and 
cerebrovascular disease events (E) in cohorts from the general population.
Adjusted measures of risk only presented in; F indicates female only; H, high AAC vs none/less advanced; L, low AAC vs none/less 






































 http://ahajournals.org by on January 13, 2021
J Am Heart Assoc. 2021;10:e017205. DOI: 10.1161/JAHA.120.017205 17
Leow et al Aortic Calcification and Cardiovascular Risk
There are a number of strengths of this me-
ta-analysis over the previous meta-analysis in 2012.71 
Because of our broad inclusion criteria and more re-
cent search, we identified substantially more studies 
than the previous meta-analysis (n=4 studies for car-
diovascular events and n=3 studies for fatal cardio-
vascular events).71 Additionally, we used the number 
of people with an event within each group (unad-
justed estimates) from studies rather than the ad-
justed estimates of the risk or hazard ratio where the 
interpretation and validity can be problematic when 
studies adjust for different baseline confounders. 
Additionally, we used subgroup analyses and me-
ta-regression to attempt to explain observed hetero-
geneity and identified a number of confounders that 
are likely to contribute to the observed heterogeneity. 
Finally, we undertook sROC analysis to determine the 
discriminative performance of AAC alone for future 
cardiovascular events, cardiovascular deaths, and 
all-cause mortality. As such, this meta-analysis can 
inform patients and their treating physicians about 
their likely future cardiovascular risk and prognosis 
when AAC is observed.
In regards to limitations, considerable differences 
between cut points of AAC, even within the same 
imaging modalities, make interpretation of the results 
challenging. As such, we cannot propose a potentially 
useful threshold based on the current meta-analysis. 
Further individual patient level meta-analyses within 
the same imaging modalities are needed. Second, 
small-study publication bias was identified for cardio-
vascular events in the CKD population and all-cause 
mortality in the general population and may have 
compromised the validity of our results. As such, the 
reported estimates should be considered tentatively. 
Finally, in some cases, study demographics may have 
influenced the imaging modality used; for example, 
younger cohorts from the general population were 
more likely to have CT or standard radiographs (range, 
60–68 years), while DXA-based imaging was predomi-
nantly in elderly women (range, 68–80 years) captured 
during bone density testing.
It is now clear that even in populations considered 
at high risk of cardiovascular disease but sometimes 
overlooked, such as the elderly and those with CKD, 
severe AAC identifies those at substantially higher ab-
solute and relative risk. Potential uses for this informa-
tion include aiding treatment decisions and increased 
patient awareness of disease risk and symptoms as a 
motivational tool for lifestyle decisions and changes, 
improving individual risk prediction and providing novel 
targets for new treatments.
In conclusion, future studies should focus on 
standardization of AAC assessment and reporting 
and investigate whether the knowledge of AAC im-
proves primary prevention and clinical management 
strategies. Given that AAC can be quickly and easily 
captured using low to negligible radiation exposure 
compared with assessing coronary artery calcifica-
tions, it may complement existing early detection and 
primary prevention strategies for clinical cardiovascular 
disease.
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Data S1. Newcastle-Ottawa scoring  
NEWCASTLE - OTTAWA QUALITY ASSESSMENT SCALE - CASE CONTROL 
STUDIES 
Note: A study can be awarded a maximum of one star for each numbered item within the 
Selection and Exposure categories. A maximum of two stars can be given for Comparability. 
Selection 
1) Is the case definition adequate? 
a) yes, with independent validation * 
b) yes, e.g. record linkage or based on self-reports 
c) no description 
2) Representativeness of the cases 
a) consecutive or obviously representative series of cases * 
b) potential for selection biases or not stated 
3) Selection of Controls 
a) community controls * 
b) hospital controls 
c) no description 
4) Definition of Controls 
a) no history of disease (endpoint) * 
b) no description of source 
Comparability 
1) Comparability of cases and controls on the basis of the design or analysis 
a) study controls for CVD risk factors  (Select the most important factor.)  * 
b) study controls for any additional factor *  (This criterion could be modified to 
indicate specific control for a second important factor.) 
Exposure 
1) Ascertainment of exposure 
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b) structured interview where blind to case/control status * 
c) interview not blinded to case/control status 
d) written self-report or medical record only 
e) no description 
2) Same method of ascertainment for cases and controls 
a) yes * 
b) no 
3) Non-Response rate 
a) same rate for both groups * 
b) non respondents described 
c) rate different and no designation 
 
NEWCASTLE - OTTAWA QUALITY ASSESSMENT SCALE - COHORT STUDIES 
Note: A study can be awarded a maximum of one star for each numbered item within the 
Selection and Outcome categories. A maximum of two stars can be given for Comparability 
Selection 
1) Representativeness of the exposed cohort 
a) truly representative of the average population (e.g., general population or CKD 
patients) of that age in the community *  
b) somewhat representative of the average population (e.g., general population or CKD 
patients) of that age in the community * 
c) selected group of users e.g., nurses, volunteers 
d) no description of the derivation of the cohort 
2) Selection of the non-exposed cohort 
a) drawn from the same community as the exposed cohort * 
b) drawn from a different source 
c) no description of the derivation of the non-exposed cohort  
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a) secure record (e.g., surgical records) * 
b) structured interview * 
c) written self-report 
d) no description 
4) Demonstration that outcome of interest was not present at start of study 
a) yes * 
b) no 
Comparability 
1) Comparability of cohorts on the basis of the design or analysis 
a) study controls for previous history of cardiovascular disease * 
b) study controls for any additional conventional cardiovascular risk factors *    
Outcome 
1) Assessment of outcome  
a) independent blind assessment *  
b) record linkage * 
c) self report  
d) no description 
2) Was follow-up long enough for outcomes to occur 
a) yes (select an adequate follow up period for outcome of interest) * 
b) no 
3) Adequacy of follow up of cohorts 
a) complete follow up - all subjects accounted for *  
b) subjects lost to follow up unlikely to introduce bias - small number lost - > 20% lost 
to follow up, or description provided of those lost) * 
c) follow up rate < 20% and no description of those lost 
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Results 
All studies provided a clear description of how exposure (amount of AAC) was ascertained, 
however there was significant variability in between-study test characteristics and methods of 
measurement. Scores used to determine AAC varied between the 52 studies, 19 studies (37%) 
used thresholds based on the Kauppila AAC 8 or 24 score, 14 studies (27%) used the presence 
vs. the absence of AAC, 7 studies (13%) used thresholds based on the AAC index (ACI), 5 
studies (10%) used thresholds based on Agatston score and the remaining 7 studies (13%) used 
other scoring methods. Only 15 studies (30%) provided evidence that prevalent cardiovascular 
disease was not present at the beginning of the study. The majority of studies (94%) adjusted 
for conventional cardiovascular risk factors or additional disease-specific risk factors. 
However, only 11 studies (21%) provided adjustment for the history of cardiovascular disease. 
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Table S1. Search strategy. 
Keyword MEDLINE Embase 




exp Vascular Calcification/ or exp 
Calcinosis/ or exp Vascular 
Diseases/ or arterial 
calcification.mp. or exp 
Arteriosclerosis/ or exp Arterial 
Occlusive Diseases/ or exp Aortic 
Diseases/ or aortic.mp. or vascular 
calcifications.mp. or exp Vascular 
Calcification/ and abdomin$.mp. 
and aortic calc$.mp. 
vascular calcification.mp. or exp 
blood vessel calcification/ or 
artery calcification.mp. or exp 
artery calcification/ or exp 
coronary artery disease/ or exp 
aorta atherosclerosis/ or exp aorta 
disease/ or exp arteriosclerosis/ or 
arteriosclerosis.mp. or exp 
atherosclerosis/ or exp 
atherosclerotic plaque/ or 
extracoronary.mp. and 




prognosis.sh. or diagnosed.tw. or 
cohort$.mp. or predictor$.tw. or 
death.tw. or exp models, statistical 
 
prognosis.sh. or diagnosed.tw. or 
cohort$.mp. or predictor$.tw. or 
death.tw. or exp models, statistical 
 
Comparator = None No search strategy No search strategy 
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Table S2. Detailed GRADE assessment for outcomes in people recruited from the general population*.  
 Quality of assessment (Decrease in quality score) Effect 
size/dose 
response 
Summary of findings 
Studies† 

















imprecision 0/↑1 1.83 (1.40-2.39) 
I2=87%,  
p-value<0.001 Moderate 
Fatal cardiovascular events 

























imprecision ↑1/ ↑1 1.98 (1.55-2.53) 
I2=90%,  
p-value<0.001 Moderate 
Coronary heart disease events 
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* All outcomes are considered clinically important. Scores are based on the GRADE for assessment of evidence about prognosis where the 
evidence begins as high quality evidence.18  These criteria are based on; a) 5 domains diminishing confidence (-1 for risk of bias, inconsistency, 
imprecision, indirectness, and publication bias) and b) 2 situations increasing confidence (+1 or +2 for large (RR >2) to very large (RR >4) effect 
size and a +1 for a dose-response gradient [increasing pooled relative risks for CV events, fatal CV events, CHD events, cerebrovascular events 
and all-cause mortality with increasing severity of AAC]).18  
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Table S3. Detailed GRADE assessment for outcomes in chronic kidney disease patients* 
 Quality of assessment (Decrease in quality score) Effect 
size/dose 
response 
Summary of findings 
Studies† 






















3.47 (2.21, 5.45) I
2=29%,  
p-value=0.196 Moderate 
Fatal cardiovascular events 











3.68 (2.32, 5.84) I2=0%, p-value=0.788 High 
All-cause mortality 











2.40 (1.95-2.97) I2=0%, p-value=0.584 High 
* All outcomes are considered clinically important. Scores are based on the GRADE for assessment of evidence about prognosis where the 
evidence begins as high quality evidence.18 These criteria are based on; a) 5 domains diminishing confidence (-1 for risk of bias, inconsistency, 
imprecision, indirectness, and publication bias) and b) 2 situations increasing confidence (+1 or +2 for large (RR >2) to very large (RR >4) effect 
size and a +1 for a dose-response gradient [increasing pooled relative risks for CV events and all-cause mortality with increasing severity of 
AAC]). 
† Number of studies with suitable data for meta-analysis 
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Table S4. The reported AAC cut-offs for studies of X-rays or DXA images.  
Study AAC24 score or equivalent AAC8 score 
CV events 0 1 2 3 4 5 6 7 8 9 10 11 12-24 
G-Bolland - 201011 0             
G-Golestani - 201026 0             
G-Lewis - 201810 0             
G-Schousboe – 200814              
G-Wilson - 200113 0             
CKD-Cho - 201733              
CKD-Claes - 201334              
CKD-Munguia - 201546              
CKD-Peeters – 201650              
CKD-Vezzoli - 201464              
CV deaths              
G-Lewis - 201810 0             
G-Rodondi - 200729 0             
G-Wilson – 200113 0             
G-Witteman - 198631 0             
CKD-Li - 201644 0             
CKD-Okuno - 200749 0             
All-cause mortality              
G-Ganz - 201225 0             
G-Lewis - 201810 0             
G-Rodondi - 200729 0             
G-Samelson – 200758* 0             
G-Szulc – 200830 0             
CKD-Disthabanchong-
201835 
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CKD-Hong - 201339 0             
CKD-Li - 201644 0             
CKD-Munguia - 201546              
CKD-NasrAllah - 201747 0             
CKD-Okuno - 200749 0             
G=recruited from the general population, CKD=recruited from the chronic kidney disease population. Green indicates the lowest reported 
category of AAC, pink indicates the moderate AAC and red indicates the highest reported category of AAC. 
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Table S5. The reported AAC cut-offs for studies using CT.  
Study Percentiles within each cohort 
 0 5 10 15 20 25 30 35 40 45 50 55 60 65 70 75 80 85 90 95 100 
CV events                      
G-Criqui – 20149                      
CKD-Hanada - 201038                      
CKD-Imanishi - 201441                      
CKD-Tatami – 20156                      
O-Davila - 200651                      
O-Parr - 201055                      
                      
CV deaths                      
G-Criqui – 20149                      
CKD-Harbaugh - 201353 0                     
CKD-Ohya - 201148                      
CKD-Tatami – 20156                      
O-Allison - 201268 0                     
                      
All-cause mortality                      
G-Criqui – 20149                      
CKD-Djuric – 20168                      
CKD-NasrAllah – 
201647* 
0                     
CKD-Ohya - 201148                      
CKD-Tatami – 20156                      
O-Allison – 201268 0                     
O-Harbaugh – 201353 0                     
G=recruited from the general population, O, recruited form other populations, CKD=recruited from the chronic kidney disease population. Zero indicated 
categorised according to the presence of AAC. Green indicates the lowest reported category of AAC, pink indicates the moderate AAC and red indicates 
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Table S6. Multivariable adjustments used for individual studies of pooled adjusted estimated of risk. 
Study reference Point estimates (HR or RR) adjusted for 
General population  
Allison 201268 age, sex, body mass index, smoking, diabetes, hypertension, dyslipidemia, and family history of CVD. 
Bolland 201011 age, systolic BP, smoking, status, history of diabetes, history of blood pressure treatment and BMI for women or 
total cholesterol for men 
Golestani 201026 age, gender, hypertension, hypercholesterolemia, diabetes mellitus, smoking, and family history of CHD. 
Hollander 200328 Adjusted for age, sex, diabetes mellitus, smoking, systolic and diastolic BP, cholesterol and HDL cholesterol, and 
history of CVD. 
Lewis 201810 Framingham risk model (using BMI) and treatment code 
Levitzky 200857 age, gender, diabetes, systolic BP, left ventricular hypertrophy on electrocardiogram, BMI, total cholesterol, 
HDL cholesterol, current cigarette smoking, and hypertension treatment. 
Rodondi 200729 age, smoking status, diabetes, systolic blood pressure, physical activity, waist girth, and history of angina and 
myocardial infarction. 
Schousboe 200814 age, systolic BP, LDL and HDL cholesterol, triglycerides, smoking, renal function, treatment assignment 
(clodronate or placebo), self-reported diagnoses of diabetes mellitus, hypertension, angina, prior stroke, and 
health status.  
Szulc 200830 age, weight, tobacco smoking, diabetes, and medications. 
Samelson 200758 age, BMI, smoking, systolic BP, total cholesterol, diabetes, CHD, and estrogen use (in women). 
Wilson 200113 age, cigarettes, diabetes mellitus, systolic BP, left ventricular hypertrophy, BMI, cholesterol, and HDL 
cholesterol  
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Table S7. Comparison of random and fixed effect estimates of studies from the general population.  
Any advanced abdominal aortic calcification Random effects RR (95% CI)  Fixed effects RR (95% CI)  
Chronic kidney diease     
Cardiovascular events  3.47 (2.21, 5.45)  3.30 (2.29-4.77)  
Fatal cardiovascular events   3.69 (2.32-5.85)  3.69 (2.32-5.85)  
All-cause mortality  2.41 (1.95-2.97)  2.41 (1.95-2.97)  
General population      
Cardiovascular events  1.83 (1.40-2.39)  1.56 (1.45-1.68)  
Fatal cardiovascular events   1.85 (1.44-2.39)  1.89 (1.68-2.13)  
All-cause mortality  1.98 (1.56-2.93)  1.49 (1.42-1.55)  
Coronary heart disease  2.23 (1.57-3.15)  1.98 (1.76-2.28)  
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Figure S1. Newcastle Ottawa scoring of studies included in the meta-analysis by a) items and b) domains. Maximum number of 
stars for each domain is 1) outcome maximum of 3 stars 2) comparability maximum of 2 stars, and 3) Selection maximum of 4 
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Figure S2. Forest plots for the pooled relative risk of a) coronary heart disease events (I2=72%, p-value=0.012) and b) 
cerebrovascular events (I2=60%, p-value=0.055) in the general population stratified by no or low abdominal aortic calcification 






























Figure S3. Meta-regression – Log RR of any CV event by top left) the proportion of women 
the study cohort (r2=0.0, p=0.012), top right), baseline systolic blood pressure (SBP) in mmHg 
(r2=0.42, p=0.003), bottom left) age group (r2=0.0, p=0.048) and bottom right) total cholesterol 
in mg/dL (r2=0.04, p=0.048). Variables tested (where sufficient studies were available n=3) 
included: age group, total cholesterol, high density lipoprotein cholesterol, % females, %type 
2 diabetics, & current smokers, BMI, SBP, % prescribed anti-hypertensives, % with clinical 














Figure S4. Meta-regression – Log RR for fatal CV events top left) imaging modality used in 
the studies (r2=0.60, p=0.029) and top right) means systolic blood pressure (SBP) in mmHg 
(r2=0.45, p=0.027) and bottom left) total cholesterol in mg/dL (r2=0.13, p=0.031). Variables 
tested (where sufficient studies were available n=3) included age group, total cholesterol, high 
density lipoprotein cholesterol, % females, %type 2 diabetics, & current smokers, BMI, SBP, 

























Figure S5. Meta-regression – Log RR of any all-cause mortality by top left) follow up time in 
year (r2=0.11, p=0.008) and top right) % of participants with type 2 diabetes (r2=0.42, p=0.003), 
bottom left) mean systolic blood pressure (SBP) in mmHg (r2=0.39, p=0.002) and bottom right) 
region of study (r2=0.36, p=0.017). Variables tested (where sufficient studies were available 
n=3) included age group, total cholesterol, high density lipoprotein cholesterol, %females, 
%type 2 diabetics, & current smokers, BMI, SBP, % prescribed anti-hypertensives, % with 
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